Gly3-Val-Cit-PAB-MMAE CAS:2684216-48-4 is a cutting-edge drug-linker conjugate designed for the development of antibody-drug conjugates (ADCs) in cancer therapy. This innovative compound features a potent tubulin inhibitor, monomethyl auristatin E (MMAE), coupled to an efficient and cleavable ADC linker, Gly3-Val-Cit-PAB. The unique combination of the MMAE payload and the Gly3-Val-Cit-PAB linker enables targeted delivery of the cytotoxic agent, resulting in potent anti-tumor activity.
Applications:
Gly3-Val-Cit-PAB-MMAE is a versatile research tool with potential applications in the design and optimization of ADCs for cancer therapy. Its superior conjugation efficiency and cleavable linker design make it an ideal candidate for the development of next-generation targeted drug delivery systems. The powerful MMAE payload, a tubulin inhibitor, disrupts microtubule dynamics, leading to cell cycle arrest and subsequent apoptosis in targeted cancer cells. By leveraging the unique properties of Gly3-Val-Cit-PAB-MMAE, researchers can explore new avenues for targeted cancer therapeutics, contributing to the advancement of more effective and safer treatments for various malignancies.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
